China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its drug candidate SKB107, formerly known as TBM-001. The study will focus on advanced solid tumor bone metastasis.
Drug Development and Mechanism
SKB107 is a radionuclide drug conjugate (RDC) co-developed with the Affiliated Hospital of Southwest Medical University. The RDC comprises small molecules as targeted ligands, combined with specialized ligation techniques, chelating agents, and therapeutic radioactive isotopes. This innovative approach aims to deliver targeted therapy for bone metastasis, a condition with significant unmet medical needs.
Clinical Trial Objectives
The clinical study will evaluate the safety, efficacy, and pharmacokinetics of SKB107 in patients with advanced solid tumor bone metastasis. By leveraging the precision of targeted ligands and the therapeutic potential of radioactive isotopes, SKB107 represents a promising advancement in the treatment of this challenging condition.-Fineline Info & Tech
Leave a Reply